Cytokinesis regulators as potential diagnostic and therapeutic biomarkers for human hepatocellular carcinoma. Issue 12 (June 2021)

• Record Type: Journal Article
• Authors: Qiao, Yiting; Pei, Yunxin; Luo, Miao; Rajasekaran, Muthukumar; Hui, Kam M; Chen, Jianxiang
• Is Part Of: Experimental biology and medicine. Volume 246:Issue 12(2021)
• Page Start: 1343
• Page End: 1354
• Publication Date: 2021-06
• Subjects: Hepatocellular carcinoma -- cytokinesis -- therapeutic targets; Physiology -- Periodicals; Biology, Experimental -- Periodicals; Medicine, Experimental -- Periodicals; 610.72
• DOI: 10.1177/15353702211008380
• Languages: English
• ISSNs: 1535-3702

Abstract

Cytokinesis, the final step of mitosis, is critical for maintaining the ploidy level of cells. Cytokinesis is a complex, highly regulated process and its failure can lead to genetic instability and apoptosis, contributing to the development of cancer. Human hepatocellular carcinoma is often accompanied by a high frequency of aneuploidy and the DNA ploidy pattern observed in human hepatocellular carcinoma results mostly from impairments in cytokinesis. Many key regulators of cytokinesis are abnormally expressed in human hepatocellular carcinoma, and their expression levels are often correlated with patient prognosis. Moreover, preclinical studies have demonstrated that the inhibition of key cytokinesis regulators can suppress the growth of human hepatocellular carcinoma. Here, we provide an overview of the current understanding of the signaling networks regulating cytokinesis, the key cytokinesis regulators involved in the initiation and development of human hepatocellular carcinoma, and their applications as potential diagnostic and therapeutic biomarkers.